{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T09:37:23Z","timestamp":1794908243634,"version":"4.9.1"},"reference-count":76,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI139092"],"award-info":[{"award-number":["R01AI139092"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the global COVID-19 pandemic, which led to hundreds of millions of human infections and more than seven million deaths worldwide. Major variants of concern, particularly the Omicron variant and its associated subvariants, can escape the vaccines developed so far to target previous strains\/subvariants. Therefore, effective vaccines that broadly neutralize different Omicron subvariants and show good protective efficacy are needed to prevent further spread of Omicron. The spike (S) protein, including its receptor-binding domain (RBD), is a key vaccine target. Methods: Here, we designed a unique mRNA vaccine encoding Omicron-KP.3 RBD based on RBD-truncated S protein backbone of an earlier Omicron subvariant EG.5 (KP3 mRNA), and evaluated its stability, immunogenicity, neutralizing activity, and protective efficacy in a mouse model. Results: Our data showed that the nucleoside-modified, lipid nanoparticle-encapsulated mRNA vaccine was stable at various temperatures during the period of detection. In addition, the vaccine elicited potent antibody responses with broadly neutralizing activity against multiple Omicron subvariants, including KP.2, KP.3, XEC, and NB.1.8.1. This mRNA vaccine protected immunized transgenic mice from challenge with SARS-CoV-2 Omicron-KP.3. Immune serum also protected against subsequent virus challenge, with the level of protection associating positively with the serum neutralizing antibody titer. Conclusions: Taken together, the data presented herein suggest that this newly designed mRNA vaccine has potential against current and future Omicron subvariants.<\/jats:p>","DOI":"10.3390\/vaccines14010078","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:13:01Z","timestamp":1768209181000},"page":"78","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Omicron KP.3 RBD-Containing Spike mRNA Vaccine Induces Broadly Neutralizing Antibodies with Protection Against SARS-CoV-2 Omicron Infection in Mice"],"prefix":"10.3390","volume":"14","author":[{"given":"Xiaoqing","family":"Guan","sequence":"first","affiliation":[{"name":"Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansam","family":"Cho","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Qian","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5955-1294","authenticated-orcid":false,"given":"Lanying","family":"Du","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_2","first-page":"677","article-title":"COVID-19 pandemic as a huge stressor of the 21st century","volume":"125","author":"Ferencova","year":"2024","journal-title":"Bratisl. Lek. Listy"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1017\/dmp.2020.277","article-title":"COVID-19 and mass fatality management: A public health challenge","volume":"14","author":"Kumar","year":"2020","journal-title":"Disaster Med. Public Health Prep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5334\/aogh.3843","article-title":"COVID-19 pandemic impact on academic global health programs: Results of a large international survey","volume":"88","author":"Rose","year":"2022","journal-title":"Ann. Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Wang, N., Shang, J., Jiang, S., and Du, L. (2020). Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00298"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Abdelrahman, Z., Li, M., and Wang, X. (2020). Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.552909"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2035057","DOI":"10.1001\/jamanetworkopen.2020.35057","article-title":"SARS-CoV-2 transmission from people without COVID-19 symptoms","volume":"4","author":"Johansson","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1473-3099(22)00053-6","article-title":"Understanding how fast SARS-CoV-2 variants transmit from household studies","volume":"22","author":"Yang","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Elrashdy, F., Redwan, E.M., and Uversky, V.N. (2020). Why COVID-19 transmission is more efficient and aggressive than viral transmission in previous coronavirus epidemics?. Biomolecules, 10.","DOI":"10.20944\/preprints202009.0076.v1"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3201\/eid2607.200282","article-title":"High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2","volume":"26","author":"Sanche","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_12","unstructured":"World Health Organization (2025, November 30). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e0082223","DOI":"10.1128\/jvi.00822-23","article-title":"Structural evolution of SARS-CoV-2 omicron in human receptor recognition","volume":"97","author":"Zhang","year":"2023","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"eabo3153","DOI":"10.1126\/sciadv.abo3153","article-title":"Intermediates in SARS-CoV-2 spike-mediated cell entry","volume":"8","author":"Marcink","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1038\/s41467-025-60406-z","article-title":"Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sarkar, M., and Madabhavi, I. (2022). SARS-CoV-2 variants of concern: A review. Monaldi Arch. Chest Dis., 93.","DOI":"10.4081\/monaldi.2022.2337"},{"key":"ref_22","first-page":"162","article-title":"SARS-CoV-2 variant biology: Immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_23","unstructured":"World Health Organization (2025, December 05). Tracking SARS-CoV-2 Variants. Available online: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Liu, H., Wei, P., Kappler, J.W., Marrack, P., and Zhang, G. (2022). SARS-CoV-2 variants of concern and variants of interest receptor binding domain mutations and virus infectivity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.825256"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"113444","DOI":"10.1016\/j.celrep.2023.113444","article-title":"Evolution of the SARS-CoV-2 Omicron spike","volume":"42","author":"Parsons","year":"2023","journal-title":"Cell Rep."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Aljabali, A.A.A., Lundstrom, K., Hromi\u0107-Jahjefendi\u0107, A., El-Baky, N.A., Nawn, D., Hassan, S.S., Rubio-Casillas, A., Redwan, E.M., and Uversky, V.N. (2025). The XEC variant: Genomic evolution, immune evasion, and public health implications. Viruses, 17.","DOI":"10.20944\/preprints202504.0496.v1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41541-024-01016-6","article-title":"Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera","volume":"9","author":"Xu","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lasrado, N., Collier, A.Y., Miller, J., Hachmann, N.P., Liu, J., Sciacca, M., Wu, C., Anand, T., Bondzie, E.A., and Fisher, J.L. (2023). Waning immunity against XBB.1.5 following bivalent mRNA boosters. bioRxiv.","DOI":"10.1101\/2023.01.22.525079"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.vaccine.2023.02.020","article-title":"Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization","volume":"41","author":"Feikin","year":"2023","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zou, Y., Huang, D., Jiang, Q., Guo, Y., and Chen, C. (2022). The vaccine efficacy against the SARS-CoV-2 Omicron: A systemic review and Meta-analysis. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.940956"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"240222","DOI":"10.1183\/16000617.0222-2024","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: A systematic review and meta-analysis of European studies published up to 22 January 2024","volume":"34","author":"Zhou","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tan, B.E.K., Tham, S.K., and Poh, C.L. (2025). mRNA vaccine development in the fight against zoonotic viral diseases. Viruses, 17.","DOI":"10.3390\/v17070960"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ymthe.2022.10.011","article-title":"Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection","volume":"31","author":"Erbar","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gote, V., Bolla, P.K., Kommineni, N., Butreddy, A., Nukala, P.K., Palakurthi, S.S., and Khan, W. (2023). A comprehensive review of mRNA vaccines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032700"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: First approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions\u2014United States, March\u2013August 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The Advisory Committee on immunization practices\u2019 interim recommendation for use of Moderna COVID-19 vaccine\u2014United States, December 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"eabj9815","DOI":"10.1126\/sciadv.abj9815","article-title":"Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B","volume":"8","author":"Liu","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ohji, G., Funakoshi, Y., Yakushijin, K., Matsutani, T., Sasaki, T., Kusakabe, T., Matsumoto, S., Koyama, T., Nagatani, Y., and Kurata, K. (2024). Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d). Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1468760"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41467-023-36110-1","article-title":"Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models","volume":"14","author":"Corleis","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1093\/infdis\/jiaf022","article-title":"Safety and immunogenicity of SARS-CoV-2 spike receptor-binding domain and N-terminal domain mRNA vaccine","volume":"231","author":"Chalkias","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Guan, X., Verma, A.K., Wang, G., Roy, A., Perlman, S., and Du, L. (2024). A unique mRNA vaccine elicits protective efficacy against the SARS-CoV-2 Omicron variant and SARS-CoV. Vaccines, 12.","DOI":"10.3390\/vaccines12060605"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105690","DOI":"10.1016\/j.isci.2022.105690","article-title":"mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41541-024-00922-z","article-title":"Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV","volume":"9","author":"Wang","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e0037624","DOI":"10.1128\/jvi.00376-24","article-title":"Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge","volume":"98","author":"Wang","year":"2024","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hirabara, S.M., Serdan, T.D.A., Gorjao, R., Masi, L.N., Pithon-Curi, T.C., Covas, D.T., Curi, R., and Durigon, E.L. (2021). SARS-COV-2 variants: Differences and potential of immune evasion. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.781429"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/10408363.2021.1979462","article-title":"The COVID-19 pandemic: Viral variants and vaccine efficacy","volume":"59","author":"Ciotti","year":"2021","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"eLife"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Chen, L., He, Y., Liu, H., Shang, Y., and Guo, G. (2024). Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1339660"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eabj5365","DOI":"10.1126\/sciadv.abj5365","article-title":"Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination","volume":"7","author":"Caniels","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.str.2024.06.012","article-title":"Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants","volume":"32","author":"Li","year":"2024","journal-title":"Structure"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., and Chakraborty, C. (2023). A detailed overview of SARS-CoV-2 Omicron: Its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses, 15.","DOI":"10.3390\/v15010167"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"116440","DOI":"10.1016\/j.celrep.2025.116440","article-title":"Antibody evasion and receptor binding of SARS-CoV-2 LP.8.1.1, NB.1.8.1, XFG, and related subvariants","volume":"44","author":"Mellis","year":"2025","journal-title":"Cell Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/0113894501296586240430061915","article-title":"Comprehensive analysis of Omicron subvariants: EG.5 rise, vaccination strategies, and global impact","volume":"25","author":"Sil","year":"2024","journal-title":"Curr. Drug Targets"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-021-00863-2","article-title":"SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Shah, M., and Woo, H.G. (2021). Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.830527"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14760584.2025.2487542","article-title":"Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: A pooled phase 1\/2\/3 randomized clinical study","volume":"24","author":"Ho","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1080\/17425247.2022.2131767","article-title":"Are inhaled mRNA vaccines safe and effective? A review of preclinical studies","volume":"19","author":"Jansen","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41541-025-01062-8","article-title":"A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection","volume":"10","author":"Liu","year":"2025","journal-title":"NPJ Vaccines"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Altay Benetti, A., Tan, E.Y.Z., Chang, Z.W., Bae, K.H., Thwin, M.T., Muthuramalingam, R.P.K., Liao, K.C., Wan, Y., Ng, L.F.P., and Renia, L. (2024). Design and characterization of a new formulation for the delivery of COVID-19-mRNA vaccine to the nasal mucosa. Vaccines, 12.","DOI":"10.3390\/vaccines12040409"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"eabn7842","DOI":"10.1126\/scitranslmed.abn7842","article-title":"Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses","volume":"14","author":"Sievers","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Edara, V.V., Manning, K.E., Ellis, M., Lai, L., Moore, K.M., Foster, S.L., Floyd, K., Davis-Gardner, M.E., Mantus, G., and Nyhoff, L.E. (2021). mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. bioRxiv.","DOI":"10.1101\/2021.12.20.473557"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41541-024-00957-2","article-title":"Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants","volume":"9","author":"Hajnik","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"eabq1945","DOI":"10.1126\/scitranslmed.abq1945","article-title":"Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models","volume":"14","author":"Hajnik","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1038\/s41467-023-41537-7","article-title":"mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States","volume":"14","author":"Tseng","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2023.27022","article-title":"Effectiveness of bivalent mRNA COVID-19 vaccines in preventing SARS-CoV-2 infection in children and adolescents aged 5 to 17 years","volume":"331","author":"Feldstein","year":"2024","journal-title":"JAMA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41541-023-00760-5","article-title":"The advances of adjuvants in mRNA vaccines","volume":"8","author":"Xie","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2342592","DOI":"10.1080\/21645515.2024.2342592","article-title":"Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size","volume":"20","author":"Shi","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s43856-025-00898-4","article-title":"Immune imprinting and vaccine interval determine antibody responses to monovalent XBB.1.5 COVID-19 vaccination","volume":"5","author":"Wrynla","year":"2025","journal-title":"Commun. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.immuni.2024.02.016","article-title":"Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans","volume":"57","author":"Tortorici","year":"2024","journal-title":"Immunity"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/78\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:18:10Z","timestamp":1768281490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,11]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["vaccines14010078"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14010078","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,11]]}}}